Compare BTG & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTG | BLTE |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 6.0B |
| IPO Year | 2007 | 2021 |
| Metric | BTG | BLTE |
|---|---|---|
| Price | $5.03 | $165.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $6.00 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 21.4M | 161.4K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.08 | N/A |
| Revenue Next Year | $28.46 | $492.11 |
| P/E Ratio | $34.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.57 | $60.00 |
| 52 Week High | $6.29 | $200.00 |
| Indicator | BTG | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 67.60 | 53.64 |
| Support Level | $4.74 | $146.94 |
| Resistance Level | $5.08 | $172.02 |
| Average True Range (ATR) | 0.18 | 6.67 |
| MACD | 0.11 | -0.14 |
| Stochastic Oscillator | 85.71 | 37.40 |
B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.